Plaque Psoriasis Study Enrolling
Explore a different direction for psoriasis.
The Latitude Atlas Study is comparing an investigational oral treatment, zasocitinib, to an approved oral treatment called deucravacitinib to see if it may provide a clearer future for people living with psoriasis.
- No placebo - all participants will receive either the approved or investigational drug
- Health insurance is not required to participate
- Reimbursement for time and travel may be available
You may qualify if you:
- Are 18 years of age or older
- Were diagnosed with plaque psoriasis at least 6 months ago